Drug
Ketotifen Fumarate
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Treatment Failure | 2,496 | 101.3 | 164.0 | signal |
| 2 | Eye Irritation | 637 | 37.3 | 41.3 | signal |
| 3 | Eye Pruritus | 214 | 21.1 | 21.8 | signal |
| 4 | Eye Pain | 276 | 16.2 | 16.9 | signal |
| 5 | Ocular Hyperaemia | 226 | 15.7 | 16.2 | signal |
| 6 | Eye Discharge | 44 | 14.0 | 14.1 | signal |
| 7 | Eye Inflammation | 35 | 12.0 | 12.1 | signal |
| 8 | Eyelid Oedema | 40 | 11.1 | 11.1 | signal |
| 9 | Tenderness | 34 | 10.6 | 10.6 | signal |
| 10 | Photophobia | 52 | 9.0 | 9.1 | signal |
| 11 | Lacrimation Increased | 83 | 9.0 | 9.1 | signal |
| 12 | Skin Reaction | 39 | 9.0 | 9.0 | signal |
| 13 | Ocular Discomfort | 30 | 8.9 | 9.0 | signal |
| 14 | Eye Swelling | 101 | 8.8 | 9.0 | signal |
| 15 | Hereditary Angioedema | 25 | 7.7 | 7.7 | signal |
| 16 | Foot Deformity | 26 | 7.6 | 7.6 | signal |
| 17 | Dry Eye | 111 | 7.4 | 7.5 | signal |
| 18 | Scratch | 23 | 7.2 | 7.2 | signal |
| 19 | Ankle Fracture | 29 | 6.1 | 6.1 | signal |
| 20 | Seasonal Allergy | 26 | 6.0 | 6.0 | signal |
| 21 | Paraesthesia Oral | 26 | 5.9 | 5.9 | signal |
| 22 | Ear Pain | 35 | 5.8 | 5.9 | signal |
| 23 | Sneezing | 39 | 5.6 | 5.7 | signal |
| 24 | Synovitis | 28 | 5.0 | 5.0 | signal |
| 25 | Paralysis | 22 | 5.0 | 5.0 | signal |
| 26 | Foot Fracture | 29 | 4.9 | 5.0 | signal |
| 27 | Osteoarthritis | 64 | 4.9 | 4.9 | signal |
| 28 | Muscle Tightness | 24 | 4.8 | 4.8 | signal |
| 29 | Pharyngeal Swelling | 14 | 4.7 | 4.7 | signal |
| 30 | Thinking Abnormal | 27 | 4.7 | 4.7 | signal |
| 31 | Oral Pain | 32 | 4.6 | 4.6 | signal |
| 32 | Eye Disorder | 42 | 4.1 | 4.2 | signal |
| 33 | Expired Product Administered | 41 | 4.0 | 4.0 | signal |
| 34 | Anaphylactic Reaction | 66 | 3.9 | 3.9 | signal |
| 35 | Temperature Intolerance | 12 | 3.8 | 3.8 | signal |
| 36 | Angioedema | 51 | 3.7 | 3.8 | signal |
| 37 | Conjunctivitis | 21 | 3.7 | 3.7 | signal |
| 38 | Obesity | 18 | 3.6 | 3.7 | signal |
| 39 | Eye Infection | 12 | 3.5 | 3.5 | signal |
| 40 | Vision Blurred | 146 | 3.5 | 3.5 | signal |
| 41 | Clostridium Difficile Infection | 22 | 3.3 | 3.3 | signal |
| 42 | Wheezing | 59 | 3.2 | 3.2 | signal |
| 43 | Skin Disorder | 33 | 3.2 | 3.2 | signal |
| 44 | Generalised Oedema | 12 | 3.2 | 3.2 | signal |
| 45 | Dermatitis Contact | 11 | 3.1 | 3.1 | signal |
| 46 | Middle Insomnia | 18 | 3.1 | 3.1 | signal |
| 47 | Hypersensitivity | 174 | 3.0 | 3.1 | signal |
| 48 | Intraocular Pressure Increased | 12 | 3.0 | 3.0 | signal |
| 49 | Blister | 50 | 2.9 | 2.9 | signal |
| 50 | Wound | 23 | 2.7 | 2.7 | signal |
| 51 | Rhinorrhoea | 53 | 2.7 | 2.7 | signal |
| 52 | Psoriatic Arthropathy | 33 | 2.7 | 2.7 | signal |
| 53 | Urticaria | 134 | 2.6 | 2.6 | signal |
| 54 | Injection Site Extravasation | 10 | 2.6 | 2.6 | signal |
| 55 | Viral Infection | 26 | 2.5 | 2.5 | signal |
| 56 | Gastroenteritis Viral | 14 | 2.5 | 2.5 | signal |
| 57 | Dysphagia | 72 | 2.5 | 2.5 | signal |
| 58 | Product Packaging Issue | 7 | 2.4 | 2.4 | signal |
| 59 | Eye Haemorrhage | 10 | 2.4 | 2.4 | signal |
| 60 | Intestinal Obstruction | 28 | 2.4 | 2.4 | signal |
| 61 | Asthma | 83 | 2.4 | 2.4 | signal |
| 62 | Vitreous Floaters | 7 | 2.3 | 2.3 | signal |
| 63 | Neck Pain | 40 | 2.3 | 2.3 | signal |
| 64 | Burning Sensation | 50 | 2.3 | 2.3 | signal |
| 65 | Body Temperature Decreased | 7 | 2.3 | 2.3 | no signal |
| 66 | Drug Ineffective | 915 | 2.2 | 2.5 | signal |
| 67 | Visual Impairment | 85 | 2.2 | 2.2 | signal |
| 68 | Eyelid Ptosis | 7 | 2.2 | 2.2 | no signal |
| 69 | Oedema | 37 | 2.2 | 2.2 | signal |
| 70 | Adverse Reaction | 9 | 2.2 | 2.2 | signal |
| 71 | Poor Venous Access | 7 | 2.2 | 2.2 | no signal |
| 72 | Glaucoma | 13 | 2.2 | 2.2 | signal |
| 73 | Speech Disorder | 35 | 2.2 | 2.2 | signal |
| 74 | Hypoaesthesia Oral | 10 | 2.1 | 2.1 | signal |
| 75 | Drug Hypersensitivity | 126 | 2.1 | 2.1 | signal |
| 76 | Product Use Complaint | 10 | 2.1 | 2.1 | signal |
| 77 | Interstitial Lung Disease | 31 | 2.1 | 2.1 | signal |
| 78 | Nephropathy | 6 | 2.1 | 2.1 | no signal |
| 79 | Dysphonia | 37 | 2.0 | 2.1 | signal |
| 80 | Mydriasis | 8 | 2.0 | 2.0 | no signal |
| 81 | Ligament Sprain | 6 | 2.0 | 2.0 | no signal |
| 82 | Osteoporosis | 24 | 1.9 | 1.9 | no signal |
| 83 | Pruritus | 218 | 1.9 | 1.9 | no signal |
| 84 | Blood Pressure Increased | 87 | 1.8 | 1.8 | no signal |
| 85 | Rash Pruritic | 30 | 1.8 | 1.8 | no signal |
| 86 | Inappropriate Schedule Of Product Administration | 98 | 1.8 | 1.8 | no signal |
| 87 | Product Packaging Quantity Issue | 6 | 1.8 | 1.8 | no signal |
| 88 | Anaphylactic Shock | 14 | 1.8 | 1.8 | no signal |
| 89 | Bone Pain | 32 | 1.8 | 1.8 | no signal |
| 90 | Tuberculosis | 7 | 1.8 | 1.8 | no signal |
| 91 | Swollen Tongue | 17 | 1.8 | 1.8 | no signal |
| 92 | Joint Swelling | 65 | 1.7 | 1.8 | no signal |
| 93 | Chest Discomfort | 55 | 1.7 | 1.7 | no signal |
| 94 | Rash Erythematous | 25 | 1.7 | 1.7 | no signal |
| 95 | Face Oedema | 9 | 1.7 | 1.7 | no signal |
| 96 | Therapy Partial Responder | 8 | 1.7 | 1.7 | no signal |
| 97 | Contusion | 51 | 1.7 | 1.7 | no signal |
| 98 | Contraindicated Product Administered | 16 | 1.7 | 1.7 | no signal |
| 99 | Musculoskeletal Stiffness | 45 | 1.7 | 1.7 | no signal |
| 100 | Arthritis | 39 | 1.6 | 1.6 | no signal |
| 101 | Sleep Disorder Due To A General Medical Condition | 8 | 1.6 | 1.6 | no signal |
| 102 | Initial Insomnia | 5 | 1.6 | 1.6 | no signal |
| 103 | Product Quality Issue | 66 | 1.6 | 1.6 | no signal |
| 104 | Tooth Abscess | 5 | 1.6 | 1.6 | no signal |
| 105 | Erythema | 99 | 1.6 | 1.6 | no signal |
| 106 | Illness | 48 | 1.5 | 1.5 | no signal |
| 107 | Mobility Decreased | 34 | 1.5 | 1.5 | no signal |
| 108 | Infusion Site Pain | 6 | 1.5 | 1.5 | no signal |
| 109 | Abdominal Discomfort | 78 | 1.5 | 1.5 | no signal |
| 110 | Blood Pressure Systolic Increased | 9 | 1.5 | 1.5 | no signal |
| 111 | Dry Skin | 60 | 1.5 | 1.5 | no signal |
| 112 | Aphonia | 6 | 1.4 | 1.4 | no signal |
| 113 | Madarosis | 5 | 1.4 | 1.4 | no signal |
| 114 | Hallucination | 32 | 1.4 | 1.4 | no signal |
| 115 | Hepatocellular Injury | 6 | 1.4 | 1.4 | no signal |
| 116 | Product Dose Omission In Error | 11 | 1.3 | 1.3 | no signal |
| 117 | Insurance Issue | 6 | 1.3 | 1.3 | no signal |
| 118 | Product Availability Issue | 9 | 1.3 | 1.3 | no signal |
| 119 | Hair Colour Changes | 5 | 1.3 | 1.3 | no signal |
| 120 | Lip Swelling | 13 | 1.3 | 1.3 | no signal |
| 121 | Product Odour Abnormal | 4 | 1.2 | 1.2 | no signal |
| 122 | Bone Disorder | 7 | 1.2 | 1.2 | no signal |
| 123 | Body Height Decreased | 4 | 1.2 | 1.2 | no signal |
| 124 | Pharyngitis Streptococcal | 4 | 1.2 | 1.2 | no signal |
| 125 | Injection Site Pruritus | 24 | 1.2 | 1.2 | no signal |
| 126 | Therapeutic Product Effect Decreased | 16 | 1.2 | 1.2 | no signal |
| 127 | Oral Discomfort | 5 | 1.2 | 1.2 | no signal |
| 128 | Visual Acuity Reduced | 12 | 1.2 | 1.2 | no signal |
| 129 | Throat Irritation | 16 | 1.2 | 1.2 | no signal |
| 130 | Rash Papular | 8 | 1.2 | 1.2 | no signal |
| 131 | Rheumatoid Arthritis | 37 | 1.1 | 1.1 | no signal |
| 132 | Product Complaint | 8 | 1.0 | 1.0 | no signal |
| 133 | Eczema | 16 | 1.0 | 1.0 | no signal |
| 134 | Product Dose Omission Issue | 90 | 1.0 | 1.0 | no signal |
| 135 | Exposure Via Skin Contact | 7 | 1.0 | 1.0 | no signal |
| 136 | Poor Quality Product Administered | 3 | 0.9 | 0.9 | no signal |
| 137 | Extra Dose Administered | 11 | 0.9 | 0.9 | no signal |
| 138 | Drug Effect Decreased | 14 | 0.8 | 0.8 | no signal |
| 139 | Therapeutic Response Shortened | 8 | 0.8 | 0.8 | no signal |
| 140 | Needle Issue | 7 | 0.8 | 0.8 | no signal |
| 141 | Dermatitis Atopic | 12 | 0.8 | 0.8 | no signal |
| 142 | Skin Irritation | 11 | 0.8 | 0.8 | no signal |
| 143 | Blood Glucose Increased | 44 | 0.8 | 0.7 | no signal |
| 144 | Product Dispensing Error | 5 | 0.7 | 0.7 | no signal |
| 145 | Anorexia | 3 | 0.7 | 0.7 | no signal |
| 146 | Product Taste Abnormal | 3 | 0.7 | 0.7 | no signal |
| 147 | Hair Texture Abnormal | 3 | 0.7 | 0.7 | no signal |
| 148 | Injection Site Mass | 8 | 0.7 | 0.7 | no signal |
| 149 | Injection Site Rash | 6 | 0.6 | 0.6 | no signal |
| 150 | Injection Site Urticaria | 4 | 0.5 | 0.5 | no signal |
| 151 | Drug Effect Incomplete | 6 | 0.5 | 0.5 | no signal |
| 152 | Accidental Exposure To Product | 16 | 0.5 | 0.5 | no signal |
| 153 | Wrong Technique In Drug Usage Process | 5 | 0.4 | 0.4 | no signal |
| 154 | Injection Site Swelling | 9 | 0.4 | 0.4 | no signal |
| 155 | Pharmaceutical Product Complaint | 3 | 0.4 | 0.4 | no signal |
| 156 | Incorrect Route Of Drug Administration | 4 | 0.4 | 0.4 | no signal |